MicrosensDx collaborates with Imperial researchers to develop groundbreaking sepsis test

MicrosensDx is excited to announce that it is working with The Mayr Group at Imperial College London to develop a novel biomarker test for the early recognition of sepsis.

Persistent activation of DNA damage response in the liver after MASLD reversal

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its more advanced form, metabolic dysfunction-associated steatohepatitis, have emerged as the most prevalent liver diseases worldwide.

October 25, 2024

FTC to probe the role of middlemen in worsening drug shortage crisis

The Federal Trade Commission is launching a probe into the extent to which group purchasing organizations and wholesalers may contribute to ongoing shortages of key

February 14, 2024

Nona Biosciences partners with Alaya.bio for CAR-T therapy

Nona’s site-specific conjugation technology maintains the antibody’s binding and function. Credit: MIND AND I/Shutterstock. Nona Biosciences has partnered with biotechnology company Alaya.bio to advance CAR-T

July 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.